|Day Low/High||207.90 / 210.42|
|52 Wk Low/High||150.37 / 236.62|
Canopy Growth could be Constellation's next big growth engine.
Shareholders enjoyed a crisp day of gains after Constellation cracked open a great earnings report pre-market.
Investors and experts need more time before they go all in on cannabis.
Market experts are abuzz over Constellation's potential new inroads into the cannabis market.
It's too easy to lump all cannabis-related stocks into the moniker "marijuana." Like many other sectors, there are differentiators underneath the same way we see in semiconductors or retail or even energy. As you go down the marijuana rabbit hole, ...
With STZ's earnings beat and the potential of the CGC investment, investors are willing to pay a premium.
I have no problem blessing an investment in this name with the appropriate steps taken toward risk management.
A strong upside gap this morning really changes the picture.
Constellation looks to wine, beer, and cannabis to take it higher.
There are several avenues to invest in the potential cannabis boom -- recreational plays; medical plays; and companies that have a lot to gain from the industry but aren't reliant upon it for success.
Constellation looks like a star today after beating expectations.
Try these trades in JPM and Key to take advantage of weakness in the sector.
Painkiller manufacturers might see their profits hurt by medical cannabis in the near future.
The only other option is 'to fearfully wait' for the legal-weed industry to expand.
It is entirely possible that a business relationship with Canopy Growth will help Constellation Brands, but the charts currently suggest further risk for the beverage company.
Covered calls may be the best bet -- or wait for a dip.
This options trade combines some upside with a chance to buy TLRY at a decent price.
The cannabis company has gained DEA approval to import a cannabinoid drug into the U.S.
Expect more companies to join Coca-Cola, Molson Coors and Constellation Brands in checking out the market.
A tie-up between the two could mark the first major U.S. firm to establish a line of CBD drinks.
The latest reports about Coke looking into cannabis confirms a broader industry trend.
You don't want your money to go up in smoke.
A brewer facing challenges, a banking giant and a retail behemoth are ripe for downside plays.
Not every cannabis stock was strong on Wednesday. One significant Canadian name sure was though.
Moody's and Zacks aren't seeing the potential for CBD drinks or even THC drinks.